Phase Ib study of PF-04136309 (an oral CCR2 inhibitor) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic adenocarcinoma Meeting Abstract
| Authors: | Noel, M.; Lowery, M.; Ryan, D.; Wolpin, B.; Bullock, A.; Britten, C.; Jin, B.; Ganguly, B. J.; Taylor, C. T.; Yin, D.; Wunderlich, D. A.; Gamelin, E. C.; Linehan, D. C. |
| Abstract Title: | Phase Ib study of PF-04136309 (an oral CCR2 inhibitor) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic adenocarcinoma |
| Meeting Title: | 42nd ESMO Congress (ESMO 2017) |
| Journal Title: | Annals of Oncology |
| Volume: | 28 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2017 Sep 8-12 |
| Meeting Location: | Madrid, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2017-09-01 |
| Start Page: | mdx369.132 |
| Language: | English |
| ACCESSION: | WOS:000411324001263 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdx369.132 |
| Notes: | Meeting Abstract: 750P -- Appears on page 257 of the abstract book -- Source: Wos |
